CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.27
-0.32 (-0.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close86.59
Open86.99
Bid86.20 x 1300
Ask86.37 x 800
Day's Range85.86 - 86.99
52 Week Range58.59 - 106.67
Volume13,185,128
Avg. Volume9,726,416
Market Cap60.41B
Beta (3Y Monthly)1.44
PE Ratio (TTM)22.47
EPS (TTM)3.84
Earnings DateJan 31, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est102.78
Trade prices are not sourced from all markets
  • 3 Potential New Drugs Held Up by the Shutdown
    Motley Foolyesterday

    3 Potential New Drugs Held Up by the Shutdown

    The market's about to find out the FDA does a lot more than check lettuce.

  • Morningstaryesterday

    Morningstar Runs the Numbers: Bogle Edition

    We take a numerical look through the life and work of Vanguard founder Jack Bogle. Plus, our most popular articles and videos for the week ended Jan. 18.

  • These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
    Investor's Business Daily2 days ago

    These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts

    Biotech stocks Gilead Sciences, Biogen and Celgene are set to beat some aspects of Q4 earnings estimates, an analyst predicted, saying he expects conservative guidance.

  • Should You Load Up on JNJ Stock Before Earnings?
    InvestorPlace2 days ago

    Should You Load Up on JNJ Stock Before Earnings?

    Shares of Johnson & Johnson (NYSE:JNJ) have not been trading well, unlike the rest of the market. In fact, the JNJ has moved in the exact opposite direction as the market has over the past few several months. While the rest of U.S. stock market was taking a beating in October and November, Johnson & Johnson stock was one of a handful of names that kept on grinding higher. Of course, it helps that JNJ is a well-known blue-chip dividend stock that investors flock to for safety during bouts of volatility. In December though, investors dumped the stock after negative reports about JNJ surfaced. They allege that Johnson & Johnson failed to alert authorities that at times some of its baby powder products contained asbestos, something the company knew for decades. That's a pretty bold allegation, particularly given the vulnerability of its customer. In any regard, J&J was quick to come out in its own defense and even issued a $5 billion buyback plan. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even sector M&A -- highlighted by Bristol-Myers' (NYSE:BMY) massive $74 billion deal for Celgene (NASDAQ:CELG) -- wasn't enough to give JNJ much of a lift. Although, the price has stabilized. ### Will It Impact Earnings? The question is, will this report impact the company's fiscal fourth-quarter earnings results, which will be released before the open on Tuesday January 22nd? * 7 Companies Apple Should Consider Buying I imagine that management will address the issue from a proactive position during the company's conference call. I expect them to deny these claims and let their legal team do the heavy lifting. All management is looking to do is reassure investors that the company is not in the wrong -- not that it will be the first time it has faced a major issue though. From a quarterly perspective, it doesn't really matter. JNJ is all about building long-term moats and maintaining its place among the healthcare sector. This situation is unlikely to dethrone the company, even if it does cause some short-term waves in the stock price. Remember, many investors are in this for the long term. As it stands, analysts expect $1.95 in earnings per share for the fourth quarter, representing 12.1% growth year-over-year (YoY). That's impressive growth considering that revenue estimates actually call for a 0.1% contraction to $20.17 billion. Also worth pointing out is that earnings estimates haven't really budged even amid these baby powder reports. 30 days and 60 days ago, analysts were looking for $1.95 in earnings per share and 90 days ago they were looking for $1.96 in EPS. Current estimates call for earnings growth of 11.8% this year to $8.16 per share. However, 2019 estimates call for growth of just 5.5% to $8.61 per share. Revenue growth is expected to fall from 6.4% in 2018 to just 1.6% in 2019. In this respect, let's see where management's guidance falls and whether its better or worse than consensus expectations. ### Trading JNJ Stock So what clues do we see from JNJ stock price ahead of earnings? Shares have been consolidating nicely near $128 to $129 per share. It's a surprisingly tight coil for a stock that's been so quickly beaten down. Investors likely felt that $122 was too much of a selloff, but aren't willing to bid the name up too much ahead of an event like earnings and after a damning baby powder report. It's encouraging to see that the declining 21-day moving average did not weigh on the stock price and push it lower. Instead, JNJ stock traded right past it, like it wasn't even there. However, the stock isn't showing any willingness to trade through the 200-day moving average and ~$132 level. Investors who love JNJ for the long-term can justify adding to their position here, some $20 off the highs we saw in December. However, they should also realize that a decline down to the December lows is possible should JNJ disappoint investors next week. Also keep in mind that the market has rallied like mad over the last three weeks. A pause or decline could weigh on JNJ stock, which has largely sat out the rally this month. * 7 Retail Stocks to Buy for the Rise of Menswear From a trading perspective, I would use a close below $128 as my stop-loss. However, because earnings are involved, it's very possible that whatever direction JNJ trades in could be a gap move. On the downside, look to see if its December lows near $122 hold as support. If it can clear and close above $132, bulls may consider buying a Johnson & Johnson stock breakout. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Apple Should Consider Buying * 7 Beaten-Up Housing Stocks Due for a Bounce Back * Take Buffett's Advice: 5 Vanguard Funds to Buy Compare Brokers The post Should You Load Up on JNJ Stock Before Earnings? appeared first on InvestorPlace.

  • Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
    American City Business Journals2 days ago

    Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

    Atlas Venture-backed Kyn Therapeutics hopes to create drugs that reverse the effects of a metabolite called kynurenine, which cancer cells use to suppress the immune system and ward off attacks.

  • Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA
    Zacks3 days ago

    Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA

    Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.

  • Celgene (CELG) Earnings Expected to Grow: Should You Buy?
    Zacks3 days ago

    Celgene (CELG) Earnings Expected to Grow: Should You Buy?

    Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018
    Motley Fool3 days ago

    Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018

    Bristol's inability to compete against Merck in front-line lung cancer weighed heavily on its shares last year.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    # Celgene Corp ### NASDAQ/NGS:CELG View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $9.66 billion over the last one-month into ETFs that hold CELG are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • TheStreet.com4 days ago

    Jim Cramer: There's a Ton More Deals in the Pipe

    The acquirers are snapping up targets like mad because the targets have seen their stocks collapse from the Great Bear Market of 2018, also known as the Powell-Pow Bear market, because Jay Powell hit stocks Pow! right in the kisser when he set out his automaton rate increase plan at the beginning of October. The creation of this new financial technology payments company is a huge win for First Data shareholders who owned a $17 stock just yesterday. David Faber on CNBC reported that these two companies had been talking for months.

  • Regeneron (REGN) Sails Steady on Label Expansion of Drugs
    Zacks4 days ago

    Regeneron (REGN) Sails Steady on Label Expansion of Drugs

    Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Daily5 days ago

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • Here's How The Government Shutdown Will Affect These Medical Stocks
    Investor's Business Daily5 days ago

    Here's How The Government Shutdown Will Affect These Medical Stocks

    The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.

  • GuruFocus.com5 days ago

    David Rolfe Comments on Celgene

    Celgene (NASDAQ:CELG) challenged us for the quarter, and quite frankly, the full year, as management failed to deliver on their promising pipeline of drugs. In review of the year, Celgene came out swinging with their $9 billion acquisition of Juno in January 2018, which brought into the Celgene portfolio of drugs JCAR017 (now liso-cell, for B-cell non-Hodgkin lymphoma) and JCARH125 (BCMA for multiple myeloma). While the deal made sense as it was in Celgene's area of expertise (blood cancer) and would allow for a path to diversify the revenue base away from their blockbuster drug Revlimid, it brings the question if the purchase price was too rich or if any of their assumptions in future revenue and/or time to market for these acquired drugs were too aggressive.

  • TheStreet.com5 days ago

    Takeda Pharmaceutical CEO Talks Big Pharma Trends

    Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks5 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    # Celgene Corp ### NASDAQ/NGS:CELG View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold CELG had net inflows of $12.87 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe
    Investor's Business Daily6 days ago

    Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe

    House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.

  • Celgene (CELG) Stock Moves -0.45%: What You Should Know
    Zacks6 days ago

    Celgene (CELG) Stock Moves -0.45%: What You Should Know

    Celgene (CELG) closed the most recent trading day at $87.01, moving -0.45% from the previous trading session.

  • Reuters6 days ago

    U.S. lawmaker launches investigation into pharma drug pricing

    A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.

  • GuruFocus.com6 days ago

    David Rolfe's Wedgewood Partners 4th Quarter Client Letter

    Top fourth quarter performance detractors include Apple, Facebook, Qualcomm, Visa, and Celgene. Top fourth quarter performance contributors include Alphabet, PayPal, Core Laboratories, Fastenal, and Ulta Beauty. Top 2018 performance detractors include Celgene, Facebook, Schlumberger, Kraft Heinz and Charles Schwab.

  • CNBC6 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • CNBC6 days ago

    Biotech is in the midst of major breakout, but one technician says buyer beware

    Biotech's having a huge run, but one technician is warning about the sector.

  • Dealmaking surge confirms the stock market got far too ch...
    CNBC Videos4 days ago

    Dealmaking surge confirms the stock market got far too ch...

    Jim Cramer explains why there's been more merger and acquisition activity in recent months and says it's "just getting started."